Michael Grundman, MD, MPH, Alzheimer's Disease Clinical Trials Expert, Joins Intellect Neurosciences' Clinical Advisory Board
May 16, 2011 07:00 ET
|
Intellect Neurosciences, Inc.
NEW YORK, May 16, 2011 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
Intellect Neurosciences Files Orphan Drug Application in the United States for Its Clinical Candidate OX1 for the Treatment of Friedreich's Ataxia
April 12, 2011 06:00 ET
|
Intellect Neurosciences, Inc.
NEW YORK, April 12, 2011 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents...
Intellect Neurosciences Initiates Capital Markets Plan
April 08, 2011 14:05 ET
|
Intellect Neurosciences, Inc.
NEW YORK, April 8, 2011 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
Intellect Neurosciences, Inc. Receives New Patent on Clinical Stage Drug from the Israeli Patent and Trademark Office
April 05, 2011 06:00 ET
|
Intellect Neurosciences, Inc.
NEW YORK, April 5, 2011 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
Intellect Neurosciences Chairman & CEO Dr. Daniel G. Chain Recognized as Individual of "Extraordinary Abilities" in Alzheimer's Drug Research by the United States Government
March 10, 2011 09:57 ET
|
Intellect Neurosciences, Inc.
NEW YORK, March 10, 2011 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents...
Intellect Neurosciences, Inc. Obtains New Patent for Alzheimer's Vaccine From the United States Patent and Trademark Office ("USPTO")
March 08, 2011 10:43 ET
|
Intellect Neurosciences, Inc.
NEW YORK, March 8, 2011 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major...
Intellect Neurosciences Issues Shareholder Update
February 22, 2011 14:15 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Feb. 22, 2011 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
Intellect Neurosciences, Inc. Obtains Pharmacokinetic Profile Report From Fourteen Day Safety Trial for the Company's Lead Alzheimer's Candidate, OX1
December 27, 2010 09:21 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Dec. 27, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and multiple licenses with...
Intellect Neurosciences CEO to be "Distinguished Speaker" at Center for Business Intelligence 4th Annual Alzheimer's Drug Development Summit
December 08, 2010 07:30 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Dec. 8, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS) a biopharmaceutical company with an internal preclinical and clinical-stage pipeline, and multiple licenses with...
Intellect Neurosciences Issues Shareholder Update
November 22, 2010 07:35 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Nov. 22, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...